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ABSTRACT 
 
Problem   and significance: Off-label use of medicines is not illegal; however, it can be 
risky and harmful, or beneficial and innovative. The main problem of this practice is the 
lack of systems for monitoring adverse drug reactions, since the drugs are used in a 
manner that is not approved by regulatory agencies. For this reason public health 
protection is not guaranteed. 
 
Purpose: To identify the various systems employed in different regions to monitor/manage 
the risks and benefits of off-label use; and to ascertain their extent of implementation. 
 
Method/search strategy: Electronic and manual literature search was done. Articles 
referring to off-label medicine use were reviewed.  The literature included journal articles, 
national MRA guidelines, international guidelines, etc. The articles were sourced from 
databases such as Pubmed and Google Scholar. Data was collected from both developed 
and emerging markets. There was no limit to publication date. 
 
Findings: Pharmacovigilance systems for off-label use do exist although the degree of 
commitment and advancement differs per country. Explicit off-label laws are present in the 
developed countries but not in the developing ones. 
 
Implications of findings: Stakeholder involvement is very important in monitoring off-label 
use. Reporting of ADRs can be improved by asserting the role of off-label PV in drug 
repositioning. The regulator is under pressure to maintain public trust through efficient 
control of off-label use 
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1. Introduction 
1.1. Background 
The World Health Organisation (WHO), in (WHO, 2002) and Pal, Duncombe, Falzon, and 
Olsson, (2013), defines pharmacovigilance (PV) as the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other drug-
related problem. According to WHO, the aims of PV are; 
 To strengthen patient care and public safety with regards to the use of medicines 
 To support public health programmes through provision of reliable, balanced 
information for proper risk-benefit profile assessment of medicines, thereby 
encouraging their safe, rational and more effective (including cost-effective) use. 
Off-label use of medicines on the other hand, is described by Stafford (2008) as the 
prescription of medicines in a way that is different from that approved by the regulatory 
authority such as the Food and Drug Administration (FDA) of the United States; that is, the 
medicine is used outside the provisions of the Summary of Product Characteristics (SPC) 
as described by Horen, Montastruc, and Lapeyre- Mestre (2002). 
Stafford (2008) and Gillick (2009) state that off-label use of medicines is legal and 
common in many countries and entails the prescription of a drug in different populations, 
conditions and even in varying doses than those it was licensed for. Gillick (2009) also 
highlights the benefits of off-label prescribing such as its use in paediatrics and finding new 
uses for existing drugs (drug repurposing). The disadvantages of this practice however, as 
stated by Gillick (2009), are the concerns about patient safety with drugs that have a high 
potential for toxicity as well as economic issues when these drugs are costly. The use of 
drugs in unregistered situations is pervasive. For instance, it is estimated in Walton, 
Schumock, Lee, Alexander, Meltzer and Stafford (2009) that off-label medicines use in the 
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US is more than 20% of out-patient prescriptions. A European study done in five 
countries, as discussed in Morales-Carpi, Estañ, Rubio, Lurbe, Morales-Olivas (2010), 
found that 67% of patients that were interviewed got at least one off- label prescription; and 
up to 90% of patients in neonatal intensive care wards receive off-label prescriptions. 
1.2. Statement of the problem 
Granted, off-label use has both advantages and disadvantages. However, the concern is 
that as much as off-label use is not illegal, systems and efforts are not put in place to 
extensively monitor the adverse drug effects in these situations. Thus the patients and the 
general public are not protected, but exposed to potential harm due to treatments that are 
not based on proven evidence. After the benefits have been identified, what are the risks 
and are they monitored and reported? 
In Mukattash, Millership, McElnay and Collier (2008), Gillick (2009) and Rodwin (2013), it is 
mentioned that off-label use exposes patients to a considerable degree of risk especially in 
the paediatric population and when the drugs have a high potential for toxicity; they also 
contribute to increased medical costs. The authors further state that there are also legal 
and ethical implications if the patients are not informed of the potential risks and the harms 
actually occur. 
PV systems and activities to regulate and monitor safety of off-label medicines use are not 
in place. These activities include availability and implementation of the relevant regulatory 
framework such as legislation, policies, guidelines, education and training. 
Rodwin (2013) indicates that the public policy that is currently available ‘fails to track, 
evaluate, or manage off-label drug use effectively’, and as a result the regulatory 
authorities that are meant to protect the public and regulate the pharmaceutical industry 
may become corrupted and hence put the public health in danger. 
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1.3. Significance and relevance of the study 
The World Health Organisation (WHO, 2002) also states that the science of PV includes 
other issues such as the use of drugs in unapproved conditions for which there is not 
enough scientific evidence. This study will ascertain if this WHO recommendation is applied. 
As highlighted by Barratt and Frai (2012) and Boguski et al (2009), off-label medicine use 
as a drug repurposing mechanism offers a more cost effective and environmentally 
friendly method of drug development as it seeks to maximise the potential benefits of a drug 
that is already in the market. Therefore, as stated by Boguski (2009) and Flower (2013); the 
initial aims of PV of detection and characterisation of only adverse drug effects are 
broadened as the side effects are now positively exploited in drug development; this is 
termed ‘type 2’ PV or repurposed PV. 
1.4. Purpose of the study 
The aim of the study is to determine the availability of pharmacovigilance systems 
employed in the regulation and monitoring of off-label use of medicines in the different parts 
of the world. The identified activities are also ascertained for whether they are 
implemented, in the pipeline, or just recommendations. 
In the process, the study also aspires to highlight the importance of PV or post- marketing 
surveillance in off-label drug use and to emphasize the growing importance and dynamism 
of PV. 
2. Off-label use of medicines 
2.1. Background 
The regulation of medicines came about due to a number of historical disasters related to 
drug use; notably the use of thalidomide in pregnancy, which resulted in babies born with 
limb deformities in the late 1950s and early 1960s. This resulted in a rapid increase in 
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medicine regulation laws and establishment of medicine regulation authorities (MRAs). In 
South Africa, the Medicines and Related Substances Act 101 of 1965 was promulgated 
and gave rise to the regulatory body, the Medicines Control Council (MCC) CTD module 
(Hibernia College 2012). 
MRAs are responsible for protection of public health through registration (or licensing) of 
medicines to ensure that when they are marketed, they meet three basic requirements of 
good quality, safety and efficacy CTD module (Hibernia College 2012) and, Regulatory 
affairs module (Hibernia College 2012). Medicines are approved only when the potential 
benefits outweigh the potential risks. Therefore, according to Boos (2003) and from CTD 
module (Hibernia College 2012), for their drug to be marketed, pharmaceutical companies 
have to submit to the MRA, pre-clinical (animal studies) efficacy and safety data, and the 
results from the clinical studies to prove the claimed safety profile and the efficacy for the 
intended use. 
In the Regulatory Affairs module (Hibernia College 2012), it is mentioned that the FDA also 
adds drug labelling, i.e. whether the drug is labelled as meeting the standards, as the forth 
medicine registration requirement. Dresser and Frader (2009) also add that the label 
includes the following approved information; 
 Indications 
 Dosage 
 Route of administration 
 Patient population 
 Age group 
Off-label use of medicines consequently implies that the above elements are defied. As 
indicated earlier, the practice of off-label use is legally and clinically acceptable; Boos 
(2003) and Tarbarok (2000) indicate that the MRAs regulate the registration process and 
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the label, but not how the medicines are prescribed. According to Lerose, Musto, Aieta, 
et al. ( 2012) and Lindell-Osuagwu, Korhonen, Saano, et al, (2009), off-label use of 
medicines is a global phenomenon, most common in populations where it is difficult to 
conduct clinical research such as in paediatrics and oncology. 
A Finland study by Lindell-Osuagwu et al (2009), found that the use of off-label drugs in 
the paediatric wards studied was very common and as pervasive as those described in 
other regions. In Gillick (2009), it is also stated that one study showed that five mostly 
prescribed oncolytics were for off-label indications in half of cases. According to several 
reports, as highlighted by Lerose, et al. (2012) and Fallon (2008), the most drugs commonly 
used in an off-label manner are antipsychotics, oncolytics, antibacterials, anticonvulsants, 
antiasthma, and cardiovascular drugs. 
2.2. Implications of off-label use 
As already alluded to, off-label use of medicines has both advantages and disadvantages; 
which in the end, according to DeMonaco, Ayfer, and von Hippel (2006), raise a lot of 
ethical, legal, economic, regulatory and safety issues. Stafford (2008, 2012) asserts that the 
different stakeholders, namely; the pharmaceutical companies, the public, the prescribing 
doctors and the payers of medical services, have different and conflicting views in terms 
of these issues arising from the off-label use of medicines. An attempt is made to discuss 
the issues separately below even though it was a bit of a challenge as there is an overlap 
e.g. ethico-legal issues. 
 Ethical issues: the patients that receive OLU drugs are exposed to risk due to lack 
of sufficient safety data. As discussed in the Ethics module (Hibernia College, 2012) 
and by Kling (2011), the principle of non-maleficence is breached when the patient 
suffers an adverse drug reaction from this use. On the other hand, if the patient 
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benefits from OLU, the principle of beneficence is upheld as the prescriber 
exercises her duty and responsibility of promoting health. Rosoff (2011) and 
Molyneux and Bogaert (2010) further emphasize that in the case where the patient 
is not informed of the benefits and risks of OLU before administering and thus 
cannot make an informed decision, his autonomy is violated. In Italy for example, 
Molyneux et al, (2010) indicate that prescribers may be charged for criminal 
conduct if they do not obtain informed consent, especially if the patient is harmed in 
the process. In South Africa, Kling (2011) states that the requirement for informed 
consent applies only to the use of unregistered drugs, not OLU. 
 Another violation of the patient’s right is being misled into participating in clinical 
research. In Rosoff (2011) and Bennett (2004), the untested OLU of medicines is 
seen as experimental treatment of which patients have to undergo without their 
knowledge when the prescribers do not disclose the important safety facts about 
the drugs. Therefore, Bennett (2004) recommends that informed consent should be 
issued and approved by the ethics committee. Other dilemmas that are raised by 
Kling (2011) and Rosoff (2011) are how much and how detailed information to give 
to the patients regarding OLU, and also sometimes both the prescriber and the 
patient may be ignorant of the off-label status, and hence the efficacy and safety, of 
the medicine. 
 Legal issues: OLU of medicines is not illegal; however, careful consideration must 
be taken especially with other laws that deal with public safety. For example, in 
South Africa, the Consumer Protection Act (CPA) and The National Health Act 
(NHA) have a direct bearing on the OLU of drugs with respect to the conduct of 
prescribers and protection of patients. CPA stipulates that a health care 
practitioner in the process of marketing a product, may not give exaggerated, 
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misleading or deceptive information, and must correct any patient 
misunderstandings. Thus potential risks and benefits must be communicated and 
informed consent must be sought to protect the patient and avoid litigation (SASA, 
2012). The NHA also requires that the patient must be thoroughly informed of risks 
and benefits of OLU (SASA, 2012). In many jurisdictions including South Africa 
and t h e  United States, it is illegal for pharmaceutical companies to promote the 
OLU of medicines; however, the FDA does allow for circulation of journal articles 
and scientific references on unregistered new uses of registered medicines – this, 
according to Jansen (2009), is not permitted in SA. It is stated in Ventola (2009) 
that promotion of off-label use information also forms another bone of contention 
among the regulator (state), prescribers and the pharmaceutical companies. There 
is the point of view that dissemination of this information promotes transparency 
with regard to treatment choices against the view that the information poses a risk 
to public health. Jansen (2009) says that dissemination of this information by 
manufacturers is illegal in South Africa. 
 Economic issues: G i l l i c k  ( 20 09 )  s ta t e s  that OLU of medicines can be costly 
if it is not efficiently regulated, since newer and more expensive drugs such as 
biotechnology products, may be used indiscriminately. An example is mentioned in 
Mesgarpour et al (2012) where it stated that in one study off-label use of factor VII 
was found to be more common than its use in approved conditions. The issues of 
cost-effectiveness and justifiable evidence are very important in controlling the 
general use of medicines. Scarce resources are wasted when unproven medicines 
and those with insufficient scientific evidence are funded by the state. Gazarian 
(2007) also suggests that the resources could instead be used in to fund essential 
drugs and even the needed research. 
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According to Molyneux et al (2010), the EU law explicitly states that financial 
considerations should not affect the decision to obtain informed consent for OLU of 
medicines. DeMonaco et al (2006) indicate that pharmaceutical companies also gain 
financially through the increased sales of their drugs being used off-label, even 
though they do not publicly endorse this practice. 
 Regulatory issues: there is a view that OLU of medicines undermines the regulatory 
system and thus threatens public trust in the MRAs. In Boos (2003), it is estimated 
that more than 50% of treatment with any medicine is off-label, which implies that the 
regulatory requirements are violated; hence it can be inferred that the label has no 
role in the marketing of the drug. According to Molyneux et al (2010), the OLU of 
medicines is comparable to the different kinds of amendments to a marketing 
authorisation (MA), known as variations. In Regulatory Affairs module (Hibernia 
College 2012) and EU variations (2008) i t  is  s ta ted that  variations are classified 
as minor or major depending on the level of risk to public health and the effect 
it has on the quality, safety and efficacy of the drug product. Molyneux et al (2010) 
assert that OLU of medicines constitutes a major variation and thus requires prior 
MRA approval since there is an additional new indication, inclusion of a new target 
population, etc. Gillick (2009) on the other hand sees an opportunity in that OLU 
bypasses the prolonged and costly process of label modification with the FDA. In 
Pandolfini, Impicciatore et al (2002), it is stated that PV as a regulatory activity is 
extremely important in order to detect any drug related problems, especially when 
they are used outside their summary of product characteristics. 
 Clinical and Safety issues: as suggested by Stafford (2012) and Borzo (2009), 
the use on medicines off-label may be beneficial in situations where standard ‘on-
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label’ drugs have failed; for example in treating multi-drug resistant tuberculosis and 
HIV/AIDS. S ta f f o rd  (2012 )  f u r the r  su gges ts  tha t  i t may also be the only 
treatment available and accessible for rare, orphan and neglected conditions, 
cancer and populations not studied in clinical research.  
Deviation from the provisions of an MA, on the other hand, according to 
Molyneux, et al (2010), Gillick (2009) and Bennett (2004), exposes patients to 
increased harm since they may have a high potential for toxicity, and the risks of 
the OLU are not well documented. As a result, Molyneux et al (2010) indicates 
that the prescribers must conduct a benefit/risk assessment per individual as the 
risk factors may not be universal. Palčevski, Skočibušić and Vlahović-Palčevski 
(2012) highlight that OLU of drugs may result in benefit, no therapeutic effect or 
adverse drug reaction; however, if a prescriber is unwilling to use a drug in an off-
label manner, patients may be denied of potentially effective treatment. Mehta (2011) 
mentions that adverse drug reactions (ADRs) pose a great threat to the public 
health; however, many are predictable and preventable through a more rational 
use; except, for example, in off-label use because of insufficient data on safety 
profile. Horen et al (2002) write that in some studies, the results showed that a third 
to half of ADRs occurring in children were as a result of off-label use. Because very 
few drugs are tested on children, their medicines are mainly used off-label; and 
according to Okechukwu et al (2009), their doses are generally extrapolated from the 
approved adult doses. However, as argued by Okechukwu et al (2009), children are 
not small adults, their vital organs are not fully developed hence their capacity to 
metabolise drugs is not fully developed. Tomlin and Morris (2009) further state that 
elimination half-lives for preterm and neonates are normally three to nine times 
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longer than in adults. Thus there is an increased inclination for children to risks of 
ADRs. 
 Drug repurposing: Bisgin et al (2012) define drug repurposing as the system of 
discovering new uses or indications for existing drugs; and for the purpose of this 
discussion, the existing drugs are the ones approved by the relevant MRA. According 
to Boguski et al (2009) and Sekhon (2013) drug repurposing has the advantages of 
exhausting the full benefits of a drug, and of offering a cheaper, shorter and 
environmentally friendly drug development system. Dolgin (2011), Napolitano et al 
(2013) and Barrat et al (2012) assert that large amounts of money are continuously 
invested in the conventional drug discovery and development but the number of newly 
approved drugs keeps declining. In Barrat et al (2012), it is further stated that the 
number of new medical entities (NMEs) that are approved by the FDA has 
remained the same at about 25 items per annum, meanwhile, the drug research and 
development cost have gone up to over 50 per cent in the last ten years. 
OLU, viewed as creative and flexible by Gillick (2009) facilitates innovation and the 
discovery of new and important indications for old established drugs, as stated by 
Stafford (2012) and Gillick (2009). For example, beta-blockers were initially 
approved for hypertension and arrhythmias, their off-label use led to their use in 
congestive heart failure. Boguski (2009) classifies OLU of medicines as a form of 
drug repurposing. 
In WHO (2002) and Yang (2011), it is stated that ADRs or side effects can be 
used to determine structure-activity-relationships, as well as pharmacological and 
genetic factors affecting the medicines’ activity. Thus they contribute to the discovery 
of other new indications. Side effects are unwanted effects due to the drug’s ability to 
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bind to a number of different targets apart from its intended target, report Haupt et al 
(2013). 
Therefore, the basic concept as explained in Yang (2011) and Bisgin (2012) is that 
drugs that have a common side effect profile are likely to be effective in treating the 
same conditions, even possibly at a lower risk profile. Hence, as discussed by Haupt 
et al (2013), Sekhon (2013) and Bisgin et al (2012) this presents an opportunity to 
find new indications for existing drugs. For example, methotrexate, an anticancer 
drug, lists cytomegalovirus (CMV) infection as a side effect; CMV infection results 
from immunosuppression. Drugs that suppress the immune system are often used in 
patients who have undergone organ transplant to prevent rejection. Yang et al 
(2011) mention that methotrexate has been reported as used off-label to prevent 
organ rejection. They also mention that the side effect on its own can be used to hint 
on a new indication by changing the drug formulation and controlling the dose, 
instead of it being dismissed as an unwanted effect. 
Therefore, as suggested by Haupt et al (2013) and WHO (2002), it is imperative to 
do away with the negative perception of ADRs and side effects, and to develop 
measures that will allow clinical, pharmaceutical and chemical information to be 
applied to better improve the understanding of the mechanisms of action of 
drugs. 
The one challenge with drug repurposing as highlighted by Sekhon (2013) and 
Boguski et al (2009) is regarding the complexities of intellectual property protection, 
since the success of a repurposed drug seems to depend on whether the patent has 
expired or not and on regulatory exclusivity. Apparently, as stated in Boguski et al 
(2009), pharmaceutical companies are not willing to invest in costly clinical trials 
for repurposed drug without a patent protection. 
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WHO (2002) indeed recognises the importance of monitoring off-label use by widening the 
scope of PV to include the use of medicines in unapproved conditions for which there is 
insufficient clinical evidence. Hence, PV is extremely important throughout the mentioned 
issues. Detection, assessment, understanding and prevention of adverse drug reactions 
ensure reduced rate or severity of harmful effects of drugs. Consequently, public health is 
safeguarded, health care and drug development costs are reduced, and there is an 
increased availability of treatment options. Mehta (2011) and Boguski et al (2009) argue that 
PV and public health protection are not only the obligations of the drug regulators; all 
stakeholders, i.e. drug manufacturers, the health care workers and the public itself should 
be all responsible in their own right to understand, reduce and manage potential risks in 
order to attain the goal of public health protection. It is discussed in the PV module 
(Hibernia College 2012) that manufacturers are already mandated by the regulators to 
submit risk management plans and other periodic safety reports on their products, 
prescribers and patients on the other hand only report voluntarily and sporadically. The 
different roles of stakeholders are as follows: 
 Public and patients: according to Flower (2013) and Boguski et al (2009) it has 
been discovered that consumer health groups can play a big role in educating the 
general public about drug safety and also in research. In Boguski et al (2009), it is 
stated that potential beneficial side effects of old drugs can be discovered online 
through a social networking tool known as ‘crowdsourcing’. 
 Industry may facilitate research by funding the needed studies. 
 Prescribers – according to Edwards (2011), clinicians need to know about the risk-
benefit balance of drugs, their pharmacology and toxicology. They should make a 
habit of reading the drug SPCs. In general, health professionals must communicate 
among themselves and they should report both failures and successes of off-label 
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use. DeMonaco et al (2006) also believe that prescribers, as product users, are 
crucial to innovation. The authors further state that product users are the actual 
innovators rather than the manufactures, hence they support drug repurposing 
through off-label use. 
 Regulators must ensure compliance to the laws, and they must foster stakeholder 
engagement. 
The underreporting of ADRs is a big challenge globally, as reported by WHO (2002), and 
this for approved uses of medicines. It is hence the intention of this study to insist that the 
minimum requirement for any ADR reporting should be on the off-label use of medicines; 
the rest will follow; for as aptly expressed by Stafford (2008:1429), “If there are substantial 
safety concerns about approved indications, there is even greater uncertainty with regard 
to off-label uses”. 
3. Methodology 
3.1. Study design 
Electronic and manual search of literature published in English was done. Articles 
referring to off-label medicine use alone and also with PV were reviewed. ‘Unregistered’ 
and ‘incorrect’ uses were search terms used synonymously with ‘off-label’ use. Other 
alternative ‘PV’ terms used were ‘post-marketing surveillance’, ‘adverse drug 
reactions/events’. Other keywords included in the search with the word ‘drug or medicine’ 
were ‘benefits, risks, safety, repurposing, repositioning’, Summary of Product 
Characteristics (SPC) and non-compliance/breach, and regulation / control / innovation in 
off-label use. 
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The literature included journal articles, national medicine regulatory authorities (MRA) 
guidelines, international guidelines, grey literature, and so on. MRA and PV websites (e.g. 
FDA, Uppsala Monitoring Centre1) were also explored. 
The articles were sourced from databases such as Pubmed, Google Scholar (through 
access to the Hibernia College library), and general internet search. Manual search was 
conducted at my workplace resource centre. There was also communication by email with 
South Africa’s national PV office to inquire about any PV activities that related to off-label 
use of medicines. No other country PV office was contacted. An attempt was made however 
to contact the Uppsala Monitoring Centre; no response was received. 
Articles that were included in the study were those that discussed off-label use alone or with 
PV and monitoring systems. Those that discussed PV only were excluded because they 
discussed general PV. The study was also only limited to off-label use of already 
marketed drugs and not those that are unlicensed 2. However, articles that discussed 
unlicensed use were also considered in the review as the problems and management 
strategies were similar. There was no restriction as to the type of off-label use, origin of 
the article, or publication period. A fairly global representation of literature was sought i.e. 
South Africa, North and South America, Europe, Asia, etc. also bearing in mind to include 
information from both developed and emerging markets. There was also no limit to the 
publishing date, but from the articles collected, none was published before the year 
2000. 
Limitations: The biggest challenge was that many promising articles could only be accessed 
through subscription. At times the abstracts were not sufficient as they were not detailed; 
                                                          
1 Uppsala Monitoring Center (UMC) is a WHO Collaborating Centre for International Drug Monitoring. 
2 Unlicensed medicines are those that are have not been approved for marketing by the regulatory authority in a given 
country or region (e.g. tablets of an adult medicine crushed and made up into a suspension for oral administration to a 
child). 
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hence I only used the abstracts that had the required information. Other challenges 
encountered were finding relevant articles on OLU studies from the African region as the 
intention was to determine the availability of such systems especially in African countries. 
Most of the articles that linked off-label use and repurposing were accessible through 
subscription and the abstracts were not very helpful. 
3.2. Data collection and analysis 
From the articles collected, any activity or system that spoke to monitoring and 
management of off-label use and drug repurposing was noted. The following information 
was also noted; 
 The source of data, i.e. the author and date of the article 
 The type of intervention, i.e. as to whether it is a law, policy, guideline, education / 
awareness tool, etc. 
 The region or country 
 
 Implementation stage or status, i.e. whether the PV system is already in operation 
or a proposal 
 General recommendations that were not specific to a region 
The results were tabulated into two tables; promulgated laws and soft laws such as 
guidelines, policies and statements. The activities or systems were explained per region or 
country. There were also articles that gave recommendations and suggestions on how to 
manage without being specific to a country. These were discussed separately. 
4. Results 
Most articles were obtained through access to the Hibernia College library. The total 
number of full articles that met the search criteria was forty two and the abstracts were 
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eleven. In addition, other publications such as books, reports and other documents from 
different jurisdictions were sourced to consolidate the information collected from the 
articles and to get a feel of general opinion on the off-label use of medicines. From the 
search, eight regions were found to have the relevant systems, namely: South Africa, 
Australia, Brazil, Canada, Italy, UK, US and EU. The results of the search are displayed in 
two tables below. 
Table 1: The l a w s  r e l a t i n g  t o  O L U  w h i c h  h a v e  b e e n  
p r o m u l g a t e d  i n  d i f f e r e n t  r e g i o n s  
Source PV system Type Status Region 
Martens, M & 
Carbonnelle, N 
(2012) 
Regulation  
No. 1235/2010 & 
Directive 
2010/84/EU 
Law Implemented 
(2012) 
EU 
Palčevski et al 
(2012) and 
Lindell-Osuagwu, 
L. et al (2009) 
Regulation (EC) 
No. 1901/2006 
as amended 
Law Implemented 
(2007) 
EU 
Molyneux, C.G. & 
Bogaert, P (2010) 
and Bernardi, A. 
& Pegoraro, R. 
(2008) 
Law 648/96, 
Law 94/98 & 
Decree Law 
Law Implemented Italy 
Dresser, R. and 
Frader, J. (2009) 
FDA 
Amendments 
Act of 2007 & 
FDCA 
Law Implemented 
(2007) 
US 
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Table 1 shows the binding laws that regulate OLU are only available in Europe and the US. 
Each region has at least two laws. Italy also has its own laws in addition to the ones passed 
by the EU. 
Table 2: The soft laws relating to OLU which have been adopted in different regions 
Source PV system Type Status Region 
Tomlin, S. & 
Morris, H. (2009) 
Prescribing 
unlicensed 
medicines to 
children 
Guidelines Implemented UK 
Pulver, L. 
Gazarian, M. et al 
(2013) 
Guiding 
principles for 
OLU 
Guidelines Proposal Australia 
Dos Santos, L. & 
Heineck, I. (2012) 
Off-label PV 
programs 
Policy Proposal Brazil 
MCC website Reporting 
post-market 
ADRs 
Guidelines Implemented South Africa 
SA Society of 
Anaesthesiologists 
Position 
statement 
Information 
tool 
Implemented South Africa 
Ogilvie, K. & 
Eggleton, A (2014) 
Official report Information 
tool 
Implemented 
(2007) 
Canada 
Nature medicine 
(2011) and FDA 
website 
FDA Sentinel 
Initiative 
Policy Launched 
(2008) 
US 
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Hospital 
Pharmacy Journal 
Off-label case 
studies 
Information 
tool 
Implemented US 
Table 2 shows the available OLU management systems which are non-binding in the UK, 
Australia, Brazil, South Africa, Canada and the US. They range from policies and guidelines 
to information tools.  
The information from both tables was extracted from different articles stated under ‘Source’. 
The name of the activity or system was noted, the type (e.g. law, policy, guide, etc.) was 
also noted as well as whether it is practised and from which region it came. 
More information on PV legislation from different regions was also sourced from the PV 
module (Hibernia College 2012); these laws are found in the annexure segment of this 
report. 
European Union 
The EU Laws Regulation No1235/2010 & Directive 2010/84/EU were amended to affect a 
number of PV requirements such as; 
 The definition of an ADR is now wider in scope and includes effects also caused 
during OLU, misuse, abuse and medicine errors. 
 Pharmaceutical companies must maintain and make available a PV 
system master file (PSMF) which must have detailed information on safety data of a 
product that is available globally. This applies to those medicines which were 
registered from July 2012. 
 The periodic safety update reports (PSUR) requirements have also been revised. 
 Improved transparency 
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 New g o o d  p h a rm a c o v ig i l a n ce  p r a c t i c e  g u i d e l i n e s  ( GVP) t o  r e p l a c e  
Eudralex Vol9A3 in 2013. 
 MRA may demand post-marketing studies to be done at any time, depending on 
circumstances. 
Regulation (EC) No. 1901/2006 as amended, also known as the Paediatric Regulation is 
an EU law aimed at improving child health protection. It regulates the development and 
licensing of drugs intended for use in children from zero to seventeen years. This goal will 
be achieved through a number of systems including ensuring that conduct of research for 
paediatric medicines is ethical and of good quality. Children must not be exposed to clinical 
trials unnecessarily, only when they stand to benefit from the drug. Also, through the law, 
pharmaceutical companies may update the SPC of marketed drugs that are used off-label in 
children. This is achieved by submitting to the MRAs, the cumulative safety and efficacy 
data on children and conducting new paediatric trials. 
Other regulations employed in the EU for OLU of drugs include the Regulation (EC) 
No.141/2000 for orphan drugs and International Conference on Harmonisation (ICH) 
guidelines that relate to risk management and PV plans (Regulatory Affairs & PV modules, 
2012). 
Italy 
In Italy, OLU of medicines is regulated by three laws namely; 
Law 648/96 specifies the kind of drugs which are freely accessible to the patients in the 
absence of alternatives and the therapeutic proposal is acceptable. These are (a) 
innovative drugs that are available in the EU but not in Italy, (b) drugs which have 
                                                          
3 Eudralex Vol 9A. – PV guidelines for medicines used in humans published by the European Commission 
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undergone phase II clinical studies and their results are available, regardless of whether 
they are registered for the disease or not, and lastly, (c) drugs that will be used for a 
condition other than the labelled one. The drugs for OLU should be those that have 
substantial scientific evidence of efficacy and safety even if they have not been registered 
for that purpose yet. 
Law 94/98 controls the OLU of medicines in individual cases but does not allow pervasive 
use, otherwise it is deemed illegal. It supports the prescriber in using a drug in an off-label 
manner provided there is no ‘on-label’ alternative, there is evidence of efficacy from globally 
reputable sources, the patient is under the direct care of the physician and informed consent 
is obtained. 
Decree Law on the therapeutic use of drugs under clinical investigation provides for life-
threatening conditions or those that severely affect the quality of life, to be treated by 
experimental drugs as long as positive efficacy data is readily accessible. 
For all the above provisions of OLU of medicines, continuous monitoring of adverse effects 
is mandatory. 
United Kingdom (UK) 
The UK has developed a number of strategies to deal with prescribing in children. The 
above guidance addresses the prescribing of unlicensed medicines to children but it also 
addresses off-label use. One of the goals is to improve communication between the 
prescriber and the parent (and patients) through informed consent, so that risk to patients 
is minimised. The parents must be told why they are given medicines off-label and they are 
encouraged to report any ADRs that may occur during use. It also requires that all 
discharge letters (e.g. from one level of care to another) for prescriptions must be thorough 
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and have information that includes name of drug, dose, frequency, length of treatment, 
strength and dosage form. Recognising that sometimes OLU of medicines in children is 
unavoidable, prescribers are advised on steps to follow in order to avoid harm to patients 
and litigation, namely: 
 Exhaust all possible approved medicines. 
 Ensure there is sufficient scientif ic evidence, experience or both to support 
that the drug is safe and effective. 
 Document in the patient’s records, the reasons why such a treatment was given. 
The UK through its MRA, Medicines and Healthcare products Regulatory Agency (MHRA), 
has quite an extensive PV program as seen on its website. ADR reports can be accessed 
and a lot of different reports e.g. drug analysis prints, can be drawn from there. A report of 
misoprostol was generated out of interest to see what the format of the report looks 
l i k e ,  and because it is used in South Africa for termination of pregnancy; a use not 
registered with the MCC. This report is extensive (38 pages long); and lists all ADRs 
(according to system organ class) and total reports on misoprostol, as a single agent or in 
combination, from 1963 to date! 
Australia 
Gazarian, Kelly et al (2006) identified that although there is plenty of literature on the 
prevalence and consequences of off-label prescribing, there is not much in terms of guiding 
the prescribers on how to make informed decisions about the proper manner of such a 
practice. Thus they are expected to use their own judgment to determine whether they 
should prescribe a drug off-label or not. The report explains the development of a guide for 
health care workers, policy makers and funders of health care. The guidelines are meant to 
show the difference between OLU that is supported by high quality evidence and that which 
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may be justified in individual exceptional cases. The report explains how the development 
process unfolded, and what the recommendations were. Apparently the recommendations 
were adapted by the Department of Health and many hospitals. The algorithm developed 
identifies three general elements of appropriate OLU, namely; use that is justified by high 
quality evidence, use within the context of a formal research proposal, and exceptional 
use. This use must be monitored for effectiveness, outcome and adverse effects. A poster 
summarizing the guidelines and highlighting this process was developed in 2013. 
Brazil 
The Pan American Health Organisation (PAHO, 2011) indicates that PV in Latin America 
and the Caribbean is still in the early developmental stage. And like other countries, it 
faces challenges of underreporting, redundant reports of already known effects, and 
irrational use of medicines including OLU. 
A paediatric study by Dos Santos and Heineck (2012) in a Brazilian hospital showed that 
the rate of unlicensed and off-label drug prescriptions was the same as the global trend. 
This is considered as high. A number of drugs used commonly for off-label were 
identified and listed, such as salbutamol. There are few studies in Brazil on the OLU of 
medicines, and the high prevalence of OLU is a concern for Brazil’s regulatory authority, 
ANVISA. According to Dos Santos et al (2012), the authority aims to employ PV systems 
and reporting of ADRs in order to identify these drugs. 
South Africa (SA) 
The guidelines for the reporting of adverse drug reactions to the regulatory authority, 
Medicines Control Council (MCC), relate to the Regulations of the Medicines and Related 
Substances Act 101 of 1965 as amended. The definition of an ADR in the guidelines 
includes the off-label use of medicines. The main form of post-marketing surveillance is the 
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spontaneous reporting. Mehta and Dheda et al (2014) also mention other forms that include 
PV systems for immunisation, HIV and TB programs, and dermatology. The challenges 
include lack of collaboration among the programs and resource constraints. There is no 
specific off-label use surveillance program except through extraction from the spontaneous 
reports. 
There are also position statements on off-label use of medicines that come from medical 
societies in SA, such as the SA Society of Anaesthesiologists (SASA) and the South 
African Childhood Asthma Working Group (SACAWG). According to Kling (2011), 
SACAWG in publishing their childhood asthma guidelines realised that some of the drugs 
were used off-label hence a disclaimer was added stating that ‘some of the medications 
used in this guideline are used off-label but with the best evidence available’. SASA (2012), 
in its statement, acknowledges all the concerns relating to the off-label use of medicine and 
links them to the various Acts in SA that relate to public protection such as; 
 the Consumer Protection Act 68 of  2008 – informed decision making by the 
patient in a language that they understand; risks to be effectively communicated 
 the National Health Act 61 of 2003 as amended – informed consent for medical 
treatment 
 Medicines and Related Substances Act 101 of 1965 – pharmacovigilance requirements 
They also draw on regulations by the World Medical Association on the Relationship 
between Physicians and Pharmacists in Medicinal Therapy of 1999, as amended in 2010, 
and the Health Professions Council of SA Ethical Rule 2006, as amended. 
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Canada 
Fuller and Saibil (2005) highlighted political and economic challenges that limited effective 
post-marketing surveillance systems in Canada, and a major dependence on spontaneous 
reporting by healthcare workers and the public. The public, however, through consumer 
health groups have made a great impact in raising awareness to ADRs. Fuller and Saibil 
(2005) also mentioned that the low rate of reporting makes it difficult to monitor drug effects 
and take prompt action. Political directives were also issued to employ faster approval 
systems for new drugs; but no directives to improve post-marketing surveillance of drugs 
came forth. 
‘Prescription pharmaceuticals in Canada: off-label use’ is the title of the report included in 
table 2. It is one of the four phases undertaken by the government on prescription 
medicines and it seeks to present to parliament, the current state of monitoring off-label 
prescribing, to raise awareness to issues of concern (ethical, economic, clinical, etc.) and 
offer recommendations. It states for example, measures that Health Canada has taken to 
collect safety data on drugs prescribed for children (Canadian Surveillance Paediatric 
Program and Pediatric Expert Advisory Committee) but with very poor results. 
The report explicitly states that there is no system in place in the country to monitor OLU of 
medicines; and there is no official procedure for documenting and monitoring whether the 
drugs used in this way are effective. The report also uses other countries as benchmarks; 
for example, it is mentioned that in South Africa, off-label data is collected by mandating the 
prescribers to supply the indication for which a drug is prescribed. Also, in France, a newly 
registered drug may be issued a Temporary Recommendations for Use (TRUs). TRUs can 
be valid for up to three years, during which the drug can be used off-label for stated 
conditions subject to some conditions and monitoring and collection of data. 
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United States (US) 
The US was found to have numerous articles and publications (including a reference book 
titled ‘Guide to off-label prescription drugs’) on the off-label use of medicines, including its 
role in drug repurposing. According to Ventola (2009), the FDA also publishes policies 
that deal with off-label information in aspects such as regulation, distribution, evaluation, 
etc. The systems listed in this report are by no means exhaustive. 
The FDA Amendments Act (FDAAA) 2007 made a number of changes to the Federal Food, 
Drug and Cosmetics Act (FDCA) which have a bearing on the OLU of medicines as follows; 
 It has strengthened the post-marketing surveillance system that regulates approved 
drugs by increasing funding to the FDA unit responsible for monitoring safety of 
approved drugs, and to the adverse event reporting system. The aim is to create an 
active monitoring system to reduce reliance on spontaneous reporting. 
Furthermore, the FDA will be able to use information from large clinical records to 
assess product safety and OLU of drugs.  Manufactures may also be requested to 
perform post-marketing research to identify risks on time. As a result patient 
information and evidence base on OLU can be gathered. 
 The Act facilitates access to study information on OLU by providing for the public 
registration of industry sponsored studies. This will deter the manufactures from 
covering up unfavourable results of those studies. 
 The Act also authorises the FDA to step in where there is a threat to public 
safety, for example, the agency can mandate modifications to the drug label to 
reflect any newly identified risks. 
Other relevant laws include Best Pharmaceuticals for Children Act, to amend the Federal 
FDCA to improve the safety and efficacy of pharmaceuticals for children. It offers six 
 
 
 
 
  
  Page 36 of 66 
months of additional patent life to drugs tested on children. The Paediatric Research Equity 
Act on the other hand authorizes the FDA to require drug manufacturers to conduct 
research in children. 
The Sentinel Initiative comes as a result of the passing of the FDAAA. It is the first point 
discussed above. This is an active surveillance system whereby safety information relating 
to drugs and devices will be pooled from an electronic database of patients. It is meant to 
strengthen and not replace the current post-market PV systems. It is a public-private-
partnership that includes data partners, patient and health advocacy groups, academic 
institutions, health insurance companies and regulated industry. When it was launched in 
2008, it was implemented in phases aiming at accessing data from 25 million people in 
2010, and 100 million by 2012. The 2010 milestone was achieved. The idea is to have ‘near 
real time’ safety information including adverse events due to off-label use, so that timely 
decisions can be made. 
The Hospital Pharmacy Journal is an independent, peer-reviewed publication. It is intended 
for health practitioners and is committed to the promotion of safe use of medicines. One 
of the standing items in the journal is a section called ‘Off-label drug uses’. This is where 
case studies of medicines used in an off- label manner are discussed in detail including the 
number of participants, the doses given for the OLU and safety information. 
5. Discussion 
 
There is a hierarchy of laws in the different jurisdictions as discussed in Regulatory Affairs 
module (Hibernia College 2012). For example in the US, Laws are passed by the US 
Congress; they are most authoritative and are binding. Below them are Regulations and 
then Guidances. Regulations apply the Law hence they are also binding, however, 
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Guidances are not binding. In the EU, in a descending order, the laws are as thus: Treaties, 
Regulations and Directives, which are all legally binding. Soft Laws are at the bottom and 
include recommendations, guidelines and opinions; which are all not obligatory.  
The EU and US health laws are very progressive and prompt, especially in relation to 
safeguarding public health. The two regions have very established PV systems and there 
are many publications and surveillance systems that address the issue of OLU of 
medicines. Monitoring  and control of OLU is facilitated and enabled by its entrenchment 
into the binding laws, and not just in soft laws or guidelines, in which the issues of ethics, 
finance, regulation, safety etc. are addressed and thus ensure compliance to international 
guidelines such as the Helsinki Declaration. Patent issues are one of the obstacles in drug 
repurposing, the US law addresses that in the Best Pharmaceuticals for Children Act. 
From the EU as a central authority, the individual European countries also have measures 
that are legally binding to deal with OLU and protect public health. 
The Italian laws for example, highlight the principles of non-maleficence and beneficence as 
they promote the need to weigh the benefit /risk ratio and to monitor the effects of the drugs; 
they also promote respect for patient autonomy through informed consent, and finally, 
providing the drug freely upholds the principle of distributive justice where every patient who 
qualifies to be treated is not restricted on the basis of affordability. However, Bernadi et al 
(2008) highlight moral challenges in applying the law, such as when oncology drugs have 
little evidence of efficacy but are used in the final stages of the disease. Or when the law 
does not specify the degree of evidence needed to justify OLU, or when there is scientific 
evidence of efficacy and safety but the government cannot approve its use due to high cost. 
Those who may privately afford the treatment may be exposed to increased harm as they 
will be outside the safety monitoring system. The TRU system in France, as stated in 
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the Canada report, has not been running long enough to measure its impact. Off-label 
prescribing is more common for older drugs; therefore a system of following the off-label use 
of new drugs will take a long time before significant effects and extent are noted. 
According to Pal et al (2013), all countries essentially rely on the spontaneous reporting of 
ADRs for their monitoring of drug safety. However, in PAHO (2011), it is stated that 
reporting is voluntary in all countries except Spain and France where it is compulsory. 
Therefore, for the developing markets, new systems do not necessarily have to be 
introduced; the spontaneous reporting can be used to actively draw up information on off-
label use, especially in instances where such reporting includes indications and doses, such 
as in South Africa. This was also used by the Canada report as a benchmark model. It is 
also encouraging to note that in the absence of explicit regulations on OLU of medicines in 
South Africa, medical associations use the other available Acts that speak to protection of 
public health to guide their practice of OLU. 
Gazarian (2007) mentions that there are no published studies, similar to those done in the 
developed world, that assess the magnitude of off-label or unlicensed medicines use in the 
paediatric population in the developing world setting. The report further speculates the 
reasons for this as due to either a lack of awareness or interest about this issue amongst 
health care professionals in the developing world. Certainly this picture is changing as 
during the literature search for this report, there are studies that were encountered such as 
the one by Okechukwu et al (2009) on prescription pattern of unlicensed and off-label use of 
medicines in Nigerian children. The article also recommends more extensive studies to be 
conducted in Nigeria and the rest of Africa. Other articles although specific to a particular 
region, were able to offer solutions and recommendations of monitoring off-label use that 
are applicable in any setting, such as the ones found in Ventola (2009) listed below: 
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 Industry self-regulation 
 Prescriber self-regulation and monitoring 
 
 “Sunshine laws” that require declaration of conflict of interest such as financial 
relationship between prescribers and manufacturing companies 
 State registration of medical sales representatives so that they can have a 
professional code of ethics to ascribe to 
From the results above, explicit OLU laws and Acts are only found in developed markets, 
whereas the soft laws can be found in both developed and emerging markets. This implies 
that there is more OLU control and regulation in the developed countries than in the 
developing ones. This is hardly surprising as it is evident in the UMC Vigibase figure 1 
below (UMC, 2015) that shows that the main ADR reporters are the developed countries. 
The US accounts for almost half of the reports at 48.2%, while emerging markets are 
covered in the 18.3% of ‘other’. 
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Source: 
Uppsala Monitoring Centre web page 
Figure 1: UMC VigiBase4 graph showing ADR reporting distribution by country from 
January 1967 to February 2015 
The World Health Organization (WHO, 2010) estimates that medicines contribute 15% to 
30% of middle income national health budgets, and 25% to 66% in developing countries. It 
further states that in some countries, medicines are the largest health expense for poor 
families. 
This leads to problems of availability and affordability of medicines. Promotion of rational 
use of medicines is an important initiative in improving access to medicines; hence efficient 
off-label pharmacovigilance is an essential tool to achieve this objective. 
                                                          
4 VigiBase® is the name of the WHO Global ICSR database; it consists of reports of adverse reactions received from 
member countries since 1968. VigiBase is updated with incoming ICSRs on a continuous basis. 
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6. Conclusion 
There are systems and activities for off-label use pharmacovigilance in place. Some are 
efficient and advanced; while others need a boost of resources and political will to thrive. 
Drug repurposing measures can flourish where systematic off-label information is 
accessible. Consequently, reporting of adverse drug reactions will improve. 
However, off-label use of medicines poses a regulatory science nightmare. Without 
proper, solid laws and regulations, it becomes very complex for regulatory authorities to 
manage it and at the same time ensure the public that it has screened all marketed drugs 
for quality, safety and effectiveness thus protecting them from harm. These regulations instil 
confidence in the MRAs as they alleviate the concerns discussed earlier that relate to 
ethics, finance, safety, etc. It is recommended that further studies should be done on the 
following; 
 monitoring the impact of off-label PV activities 
 Prevalence and outcomes of PV type 2 
 off-label use in African countries 
7. Recommendations 
The following measures are recommended to improve the management of off- label use 
of medicines; 
 Stakeholders at all levels must be involved in the safety monitoring of medicines, 
whether they are used off-label or not. 
 International b o d i e s  s u c h  a s  W H O , m u s t  e n d o r s e  a n d  e n c o u r a g e  
pharmacovigilance in off-label use through their publications; how about, ‘A practical 
handbook on the pharmacovigilance of off-label use of medicines’ 
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 South Africa should continue to benchmark from other regions especially in 
augmenting the current systems. Also, noting that there is a proposal for a policy on 
PV systems, off-label use must be included explicitly. 
 The Australian guidelines on OLU are simplified in the form of a poster. These should 
be globally embraced especially in the developing world where there are no systems 
in place to control off-label use. 
 The WHO definition of pharmacovigilance should be revised to include its role in drug 
repurposing (Flower, 2014). 
 Risk management plans with regard to the use of medicines in general, should be 
mandatory at all levels of health care. 
 The concept of drug repurposing in general, and as a form of beneficial OLU, should 
be asserted in order to improve the reporting of ADEs. 
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TITLE 
Pharmacovigilance systems in off-label medicines use 
INTRODUCTION 
The World Health Organisation (WHO) defines pharmacovigilance as the science and 
activities relating to the detection, assessment, understanding and prevention of adverse 
effects or any other drug-related problem (WHO, 2013). WHO further stipulates the aims of 
pharmacovigilance as follows: 
 To strengthen patient care and public safety with regards to the use of medicines. 
 To support public health programmes through provision of reliable, balanced 
information for proper risk-benefit profile assessment of medicines. 
Off-label use of medicines is described by Stafford (2008) as the prescription of medicines 
in a way that is different from that approved by the regulatory authority (e.g. FDA), that is, 
the medicine is used outside the provisions of the Summary of Product Characteristics 
(SPC) (Horen, 2002). It is a common practice and it is legal since according to Boguski 
(2009), the FDA regulates the system of drug approval but not how the drug is used 
(i.e. physicians can prescribe medicines for any indication they see fit as long as they 
have run out of standard options). 
Off-label use has both advantages and disadvantages. However, the concern is that as 
much as off-label use is not illegal, systems and efforts are not put in place to extensively 
monitor the adverse drug effects in these situations. Thus the patients and the public at 
large are not protected but exposed to potential harm due to treatments that are not 
based on proven evidence. Risk-benefit ratio balance: the benefit is identified, what is the 
risk and is it monitored? 
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The study is inspired by the concept of drug repurposing (from the Research Methods 
module assessment). As indicated by Barratt et al (2012) and Boguski et al (2009), 
traditional drug development methods are costly and cumbersome; drug repurposing, or 
‘drug recycling’ is a cost-effective and environmentally friendly strategy of drug development 
that seeks to exhaust the potential benefits of an already marketed drug. Off-label use of 
prescription medicine is a form of drug repurposing (Boguski et al, 2009); however, from my 
experience and observations, systems are not in place to monitor the effects of the drugs 
used in this way. 
This brings in the issue of pharmacovigilance. Medicines can be harmful to patients; and 
normal reporting of adverse drug events is very poorly done in my work environment. 
Therefore, I feel that pharmacovigilance systems and activities should be stepped up for 
use of medicines in unregistered situations whereby there is no evidence of efficacy and 
safety. Also with the advent of drug repurposing, the additional aims of pharmacovigilance 
seem to emerge; to detect, assess, and understand favourable side effects or expanded 
spectrum of activity that may be identified during drug development or use (Boguski et al, 
2009). 
Hypothesis / research question: pharmacovigilance systems and activities to regulate and 
monitor safety of off-label medicines use are not in place. 
The activities in question are: availability and implementation of the relevant regulatory 
framework such as legislation, policies, guidelines, and education and training. 
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METHODOLOGY 
Systematic literature review of studies conducted to investigate both good and bad effects 
of off-label medicine usage. 
Data will be collected from databases such as Cochrane, Embase, Pubmed and other 
different journals, publications and proceedings. 
Data analysis will be qualitative. The relevant activities will be identified and assessed with 
regards to whether they are available, implemented or not, and whether there are any in the 
pipeline. 
ETHICAL CONSIDERATIONS 
The study will not infringe on any ethical issues as it will be based on publicly available 
information, i.e. published articles and public documents. 
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SA Adverse Drug Reactions Reporting Form 
 
 
      
 
 
 
 
Version 1: Released for implementation May 2003 
Version 2: Released for implementation November 2004 
Version 3: Updated contact details April 2011 
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ADVERSE DRUG REACTION AND PRODUCT QUALITY PROBLEM REPORT FORM 
(Identities of reporter and patient will remain strictly confidential)  
 
 
NATIONAL ADVERSE DRUG EVENT MONITORING CENTRE 
NADEMC 
The Registrar of Medicines Fax: ( 021) 448-6181 
Private Bag X 828 Tel : (021)  447-1618 
Pretoria , 0001  
In collaboration with the WHO International Drug Monitoring Programme 
PATIENT INFORMATION 
 
Name (or initials): .........................................................    Patient Reference Number: …………………………………………….. 
Sex: M F Age: ..................... DOB:  ..... / ....../ ........ Weight (kg) ................... Height (cm) .................... 
 
ADVERSE REACTION  /  PRODUCT QUALITY PROBLEM   (tick appropriate box) 
     
Adverse reaction  and/or Product Quality problem   Date of onset of reaction: ........./........../............ 
 Time of onset of reaction: ….........hour.............min 
 
Description of reaction or problem (Include relevant tests/lab data, including dates): 
 
 
 
1. MEDICINES / VACCINES / DEVICES (include all concomitant medicines) 
Trade Name & Batch No. 
(Asterisk Suspected Product) 
Daily 
Dosage 
Route Date Started Date Stopped Reasons for use 
      
      
      
      
      
      
ADVERSE REACTION OUTCOME (Check all that apply) 
    
 death  life-threatening Reaction abated after stopping medicine: Recovered:     Y  N 
 disability  hospitalisation  Y  N  N/A  Sequelae:  Y  N 
 congenital anomaly  Other................  
Event reappeared on rechallenge: 
 
Describe 
Sequelae:....................... 
 required intervention to 
prevent permanent 
impairment/damage 
.............................. ............................................................ 
 .............................. 
.............................. 
……………………. 
..............................................................
..............................................................
........................................................ 
__ 
COMMENTS: (e.g. Relevant history, Allergies, Previous exposure, Baseline test results/lab data) 
 
 
 
2. PRODUCT QUALITY PROBLEM: 
Trade Name Batch No Registration No Dosage form & strength Expiry Date Size/Type of container 
      
      
 
Product available for evaluation?: Y   N 
 
REPORTING HEALTHCARE PROFESSIONAL:  
  
NAME: ................................................................................. QUALIFICATIONS:................................................................. 
 
ADDRESS: ............................................................................... 
 
.................................................................................................... ……………………………….…………..                      …………………..  
        Signature     Date 
Postal Code: ……………      TEL: (............)......................................................    
 
This report does not constitute an admission that medical personnel or the product caused or contributed to the event.  
  
N
Y 
Y
   
N 
Rechallenge not done 
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ADVICE ABOUT VOLUNTARY REPORTING 
 
 
 
Report adverse experiences with:  
 medications (drugs, vaccines and biologicals) 
 medical devices (including in-vitro diagnostics) 
 complementary / alternative medicines (including 
traditional, herbal remedies,  etc) 
 
Please report especially: 
 adverse drug reactions to newly marketed products 
 serious reactions and interactions with all products 
 adverse drug reactions which are not clearly reflected in 
the package insert. 
 
Report Product Quality Problems such as: 
 suspected contamination 
 questionable stability 
 defective components 
 poor packaging or labelling  
 
 
 
Report even if: 
 you're not certain the product caused the event 
 you don't have all the details 
 
Important numbers: 
 
Investigational Products and Product Quality Problems:  
 fax:  (012) 395-9201  
 phone:  (012) 395-9341 
 
Adverse Events Following Immunisation:  
 fax:  (012) 395 8905  
 phone: (012) 395 8914/5  
 
 
 
 therapeutic failures 
 
 
 
Confidentiality: Identities of the reporter and patient will remain strictly confidential.  
 
 
Your support of the Medicine Control Council’s adverse drug reaction monitoring programme is much appreciated. 
Information supplied by you will contribute to the improvement of medicine safety and therapy in South Africa.  
 
 
PLEASE USE ADDRESS PROVIDED BELOW - JUST FOLD IN THIRDS, TAPE and MAIL 
 
________________________________________________________________ 
 
Postage will be paid 
by the Addressee 
Posgeld sal deur die 
geadresseerde betaal 
word 
   No Postage stamp 
necessary if posted in the 
Republic of South Africa 
Geen posseël nodig nie 
indien in die Republiek van 
Suid-Afrika gepos 
  BUSINESS REPLY SERVICE 
BESIGHEIDSANTWOORDDIENS 
  
  Free Mail Number: 
Vryposnommer: 
BNT 178 
  
     
  DEPARTMENT OF HEALTH 
DEPARTEMENT VAN GESONDHEID 
  
  REGISTRAR OF MEDICINES 
REGISTRATEUR VAN MEDISYNE 
  
  PRIVATE BAG / PRIVAATSAK X828 
PRETORIA 
0001 
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B-R legislation 
 
 
Benefit-Risk Assessment Legislation Notes 
 
 
Legal drivers for B-R assessment 
 
EU Regulation (EC) 726/2004 
 
Recital (14): Indicates that provisions related to Benefit-Risk (B-R) assessment described in Directive. 
2001/83/EC are applicable. It should be possible to assess the B-R balance of all medicinal products 
when they are placed on the market, at the time of the renewal of the authorisation and at any other 
time the competent authority deems appropriate. 
 
New pharmacovigilance (PV) legislation (Regulation (EU) No 1235/2010 and Directive 2010/84/EU) 
was adopted by the European Parliament and European Council in December 2010. 
 
New PV legislation-EU  
Directive 2010/84/EU 
 
Regulation 1235/2010 
 
• PV-related changes applicable to all products, irrespective of approval procedure, for all 
European Economic Area (EEA) countries  
 
• Came into effect 2 July for Centrally Authorised Products (CAPs) and 21 July for all other 
products, 2012  
 
Impacts on the move from Periodic Safety Update Report (PSUR) to Periodic Benefit-Risk Evaluation 
Report (PBRER) include the need to provide: 
 
• Summaries of data relevant to the benefits and risks, including results of all studies with a 
consideration of the potential impact on the marketing authorisation (MA)   
• Scientific evaluation of the B-R balance  
 
• All data relating to the volume of sales of the medicinal product and any data relating to 
prescription volume and population exposure estimates   
• ICH E2 (R2) will provide the guidance and template.  
 
New PV legislation - US 
 
US Food and Drug Administration Safety and Innovation Act (FDASIA) Prescription Drug User Fee 
Act (PDUFA) V 
 
PDUFA V goals include 'Enhancing benefit-risk assessment in regulatory decision making.' 
 
FDA's commitments: 
 
• Publish a five-year plan that describes FDA’s approach to implement a structured B-R 
framework by 31 December 2012 and begin execution by 30 September 2013  
 
• Conduct two public workshops on B-R from the regulator’s perspective that will begin by 31 
December 2013   
• Develop an evaluation plan to ascertain the impact of the B-R framework  
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B-R legislation 
 
 
• Revise templates (such as review, decision and memo) as appropriate to incorporate   
FDA’s approach  
 
B-R Assessment Initiatives  
 
US 
  
EU 
  
Global 
 
 
      
 
       
 
         
 
PDUFA V Goals Letter and European Medicines Agency  ICH E2C Draft Guidance 
 
FDA Framework (EMA) B-R Methodology  PBRER will replace 
 
Plan to conduct workshops Project  periodic safety evaluation 
 
• Patient perspective Work packages completed:  reports (PSURs) 
 
• Decision making •   Models and methods in use  Emphasis on integrated 
 
• Piloting framework on • Tools and processes  B-R evaluation 
 
 six new molecular • Field testing  Focus on qualitative 
 
 entities (NMEs) in 2012 • PrOACT framework  framework 
 
   •   Final work package will    
 
Institute of Medicine (IOM)  make recommendations to  Japan 
 
Calls for the FDA to develop  incorporate into routine  Three-year project to 
 
a single, comprehensive  practice  enhance risk 
 
document that tracks B-R     management, including 
 
and Risk Management EU Good PV Practice  approaches to B-R 
 
(BRAMP) over the life cycle B-R assessments in:  assessment 
 
   • Periodic reporting    
 
Pharmaceutical  Research • RMPs  COBRA/CASS Initiative* 
 
and   Manufacturers   of • License renewals  Qualitative B-R pilot 
 
America (PhRMA) Benefit     project to develop and 
 
Risk Action Team (BRAT) Innovative Medicines  implement a framework 
 
framework Initiative (IMI) PROTECT  for use among regulatory 
 
Development of a flexible Focused work stream on B-R  agencies, including 
 
framework to promote assessment and the  Canada, Australia, 
 
transparent, systematic B-R development of B-R  Singapore and 
 
assessments and enhance visualizations  Switzerland 
 
communication among       
 
stakeholders       
 
         
 
 
 
Several B-R initiatives have been initiated globally over last 15 years and momentum has increased 
exponentially with time. 
 
Despite regional preferences, there is momentum toward a standardized, global approach that 
includes the: 
 
• Development and rise of frameworks for organizing data and structuring B-R discussions   
• Introduction of more specialized quantitative methodologies  
 
Visualization and communication of B-R assessments are key outcomes for these initiatives. 
 
The recognition of the important differences in perspective (patient, prescriber, regulator or payer) for 
any given B-R assessment has emerged. 
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Leading Frameworks: 2012 
 
FDA EMA COBRA/CASS   BRAT  
 
Structured PrOACT-URL Qualitative Structured, transparent 
 
qualitative approach Problem framework to framework for  
 
identifying key Objectives support assessing and  
 
issues for B-R Alternatives regulatory communicating the B-R 
 
deliberations Consequences decision making profile   
 
 
Trade-offs in CASS Value Tree Example with Identified and Potential Benefits and Risks       
 
 
Uncertainty countries 
 
Cancer Prostate cancer incidence        
   Angina requiring CABG   
  Cardiovascular Coronary heart disease death   
    Issues Lipid levels meet target   
 
Risk tolerance 
 Benefits  Non-fatal myocardial infarction   
   Cognitive Issues 
Dementia incidence Identified benefit      or risk category  
     Potential outcome  
    
Ischemic Stroke Fatal ischemic stroke or B/R category   
Linked 
 
Benefit-  Benefit/risk     Non-fatal ischemic stroke  
  Risk   outcome  
  Balance  
Hepatitis with hospitalization         
   
Liver Damage Hepatitis without hospitalization    
decisions 
     
    Liver failure   
  
Risks  Persistently Elevated Transaminases         
    Myopathy   
    Muscle Damage Rhabdomyolysis   
     Severe rhabdomyolysis leading to kidney failure   
 
 
 
 
Developed with the B-R Commissioned in Progressively 
goal of improving Methodology 2008 developed over a six- 
transparency in Project  year period using 
decision making introduced in Led by Centre for hypothetical and real- 
 2009 Medicines world examples 
Better  Research (Stuart  
communication  Walker)  
Which B&R were    
considered    
How evidence is    
interpreted    
How B&R were    
weighed    
Piloted via six case The Committee Currently being PhRMA Pilot Initiative 
studies of past for Medicinal piloted completed 2011 
regulatory decisions Products for   
 Human Use  BRAT Framework 
Road tested with an (CHMP)  transitioned to the 
additional two cases assessment  Centre for Innovation in 
studies templates have  Regulatory Science 
 included a list of  (CIRS) in 2012 for 
Currently being B-R criteria  broadened input and 
evaluated in 'live' since Oct. 2009  further development 
reviews with    
consideration for B-R   
implementation into Methodology   
the review process Project aims to   
 adapt or   
 develop tools   
 for B-R   
 assessment   
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FDA 
 
The B-R framework is designed to 'tell the story' of the regulatory decision, with the therapeutic area 
questions to be addressed. 
 
Severity of condition  
What is the condition that is treated or prevented by the drug? 
 
What are the clinical manifestations of the condition; what is the natural history; does severity vary 
across sub-populations? 
 
Unmet medical need 
 
What other therapies (approved and off-label therapies, including non-pharmacological) are available? 
 
How effective or well tolerated are alternatives, and what is the evidence? 
 
Clinical benefit  
It is more product specific and utilizes questions such as: 
 
• What trials (including strengths and weaknesses) were conducted to establish efficacy?   
• What endpoints were evaluated; are they clinically meaningful?   
• Did the benefits vary across sub-populations of responders?  
 
Risk  
Characterize the safety concerns identified in the clinical trials, including: 
 
• Incidence of a particular risk in study population or variation in sub-population  
 
• Range in the severity of the risk, noting if it changes with continued exposure, and if it is 
reversible when treatment stopped  
 
How might incidence of risk change in the post-approval space? Is further characterization of risk 
needed? 
 
Risk management 
 
Which risks (if any) require mitigation or further characterization? What tools or methods are best to 
assess or mitigate these risks? What is the expected contribution of each methodology or tool to the 
overall RMP? 
 
What would be the ideal risk management plan? How should effectiveness be measured? If the 
desired impact is not achieved, at what point should the risk management plan be re-evaluated? 
 
EMA 
 
The EMA uses a qualitative framework (PrOACT-URL) for structured decision making, which is useful 
with or without additional quantitative methodologies, it includes 8 steps: 
 
1. Problem: Determine the nature of the problem and its context.   
2. Objectives: Identify criteria of favourable and unfavourable effects.   
3. Alternatives: Identify the options to be evaluated against the criteria.   
4. Consequences: Describe how the alternatives perform for each of the criteria.  
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5. Trade-offs: Assess the balance among favourable and unfavourable effects.   
6. Uncertainty: Assess the uncertainty associated with the effects.   
7. Risk tolerance: Judge the relative importance of the decision maker’s risk attitude.   
8. Linked decisions: Consider the consistency of this decision with past decisions.  
 
COBRA/CASS 
 
• Coordinated by the Center for Innovation in Regulatory Science, CASS is a consortium of 
regulatory agencies from Canada, Australia, Switzerland, and Singapore (CASS). The 
objective of the CASS initiative is to develop a systematic and standardized approach to 
benefit-risk assessment in order to facilitate joint or shared reviews among the four agencies. 
The consortium has established project teams at the respective agencies, developed a draft 
electronic summary and pro forma template that summarizes and contextualizes B-R 
decisions, and undertaken demonstration projects using the draft pro forma with agency pairs 
assessing the same drug at the same time. The CASS initiative has been renamed COBRA: 
(Consortium On Benefit Risk Assessment )  
 
BRAT 
 
A structured, transparent approach for B-R assessment is the 'BRAT framework'. The BRAT 
framework is a six-step process with an adaptable structure that can be used for a broad range of 
pharmaceutical B-R assessments. The framework comprises a set of processes and tools that 
guides decision makers in selecting, organizing, summarizing, and communicating evidence relevant 
to B-R decisions. It is designed for use throughout the life cycle of a drug for decision making and as 
a means to improve dialogue with regulators and other stakeholders. 
 
 
 
 
 
